Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Diaz-Padilla

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|April 6, 2011
Epothilones in the treatment of ovarian cancerIvan Diaz-Padilla, Amit M Oza
Expert Opinion on Investigational Drugs|March 12, 2011
Brivanib alaninate for cancerIvan Diaz-Padilla, Lillian L Siu
Investigational New Drugs|March 6, 2009
Cyclin-dependent kinase inhibitors as potential targeted anticancer agentsIvan Diaz-Padilla, Lillian L Siu, Ignacio Duran
Journal for Immunotherapy of Cancer|July 9, 2025
Therapeutic potential of targeting LAG-3 in cancerDiwakar Davar, Ana Carrizosa Anderson, Ivan Diaz-Padilla
The Cochrane Database of Systematic Reviews|March 18, 2011
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent diseaseAlbiruni Ryan Abdul Razak, Louise Li, Andrew Bryant, et al.
Cancer Treatment Reviews|March 3, 2012
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancerIvan Diaz-Padilla, Ignacio Duran, Blaise A Clarke, et al.
Critical Reviews in Oncology/Hematology|August 14, 2012
Treatment of metastatic cervical cancer: future directions involving targeted agentsIvan Diaz-Padilla, Bradley J Monk, Helen J Mackay, et al.
Gynecologic Oncology|November 9, 2011
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic reviewIvan Diaz-Padilla, Eitan Amir, Sharon Marsh, et al.
Gynecologic Oncology|March 25, 2014
Circulating and disseminated tumor cells in ovarian cancer: a systematic reviewNuria Romero-Laorden, David Olmos, Tanja Fehm, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|April 6, 2011
Epothilones in the treatment of ovarian cancerIvan Diaz-Padilla, Amit M Oza
Expert Opinion on Investigational Drugs|March 12, 2011
Brivanib alaninate for cancerIvan Diaz-Padilla, Lillian L Siu
Investigational New Drugs|March 6, 2009
Cyclin-dependent kinase inhibitors as potential targeted anticancer agentsIvan Diaz-Padilla, Lillian L Siu, Ignacio Duran
Journal for Immunotherapy of Cancer|July 9, 2025
Therapeutic potential of targeting LAG-3 in cancerDiwakar Davar, Ana Carrizosa Anderson, Ivan Diaz-Padilla
The Cochrane Database of Systematic Reviews|March 18, 2011
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent diseaseAlbiruni Ryan Abdul Razak, Louise Li, Andrew Bryant, et al.
Cancer Treatment Reviews|March 3, 2012
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancerIvan Diaz-Padilla, Ignacio Duran, Blaise A Clarke, et al.
Critical Reviews in Oncology/Hematology|August 14, 2012
Treatment of metastatic cervical cancer: future directions involving targeted agentsIvan Diaz-Padilla, Bradley J Monk, Helen J Mackay, et al.
Gynecologic Oncology|November 9, 2011
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic reviewIvan Diaz-Padilla, Eitan Amir, Sharon Marsh, et al.
Gynecologic Oncology|March 25, 2014
Circulating and disseminated tumor cells in ovarian cancer: a systematic reviewNuria Romero-Laorden, David Olmos, Tanja Fehm, et al.
Cancer|October 4, 2014
Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancerVincent Castonguay, Michelle K Wilson, Ivan Diaz-Padilla, et al.
Pageof 4